Side Effects of Drugs Annual

A Worldwide Yearly Survey of New Data in Adverse Drug Reactions

1st Edition, Volume 44 - November 23, 2022
Editor: Sidhartha D. Ray
Language: English
Hardback ISBN:
9 7 8 - 0 - 3 2 3 - 9 8 9 0 9 - 1
eBook ISBN:
9 7 8 - 0 - 3 2 3 - 9 8 9 1 0 - 7

Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 44, first published in 1977, presents clinicians and medical investiga… Read more

Purchase options

World Book Day Celebration!

Save up to 30% on books and eBooks!

Shop now

Institutional subscription on ScienceDirect

Request a sales quote

Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data in Adverse Drug Reactions, Volume 44, first published in 1977, presents clinicians and medical investigators with a critical survey of new data and trends in adverse drug reactions and interactions. Topics covered in this new release include Thyroid hormones, Iodine and Iodides, and Antithyroid Drugs, Side Effects of Antidepressant Medications, Side Effects of Lithium, Side Effects of Opioid Analgesics and Narcotic Antagonists, Side Effects of Beta-lactams and Tetracyclines, Side effects of Anti-diabetic Drugs, Vaccines, Side Effects of Neuromuscular Blockings Agents and Skeletal Muscle Relaxants, and much more.

Other chapters cover General Anesthetics and Therapeutic Gases, Drugs that Act on the Respiratory Tract, Positive Inotropic Drugs and Drugs Used in Dysrhythmias, Metals and Metal Antagonists, Antiseptic Drugs and Disinfectants with special scrutiny of COVID-19 pandemic related side effects, Drugs in tuberculosis and leprosy, Anthelminthic drugs, Blood and blood treatments, and a variety of other topics.

Cover
Title page
Table of Contents
Copyright
Contributors
Preface
Special Reviews in SEDA 44
Table of Essays, Annuals 1–43
Abbreviations
Focus on pharmacogenomics, phytonutrient–drug interactions and COVID-19 vaccines: Perspectives on ADRs, ADEs, and SEDs
Introduction
Pharmacogenomic considerations
Immunological/hypersensitivity reactions
Vaccine-induced adverse effects
Analysis of toxicological reactions
Phytonutrient–drug interactions
Grades of adverse drug reactions
FDA pregnancy categories/classification of teratogenicity
References [Clinicians are suggested to be aware of the information contained in the following literature originating from regulatory agencies; Readers are advised to follow the most up-to-date info posted on respective websites prior to advising patients]
Conclusion
Chapter 1: Lithium
Abstract
Introduction
Cardiovascular
Nervous system
Neuromuscular
References
Chapter 2: Antipsychotic agents
Abstract
Introduction
FGAs
SGAs
Olanzapine
Aripiprazole
Risperidone
Drug interaction
Conclusion
References
Further reading
Chapter 3: Drugs acting on the cerebral and peripheral circulations
Abstract
Drugs used in the treatment of migraines
References
Chapter 4: Side effects of antidepressants
Abstract
Introduction
Antidepressant side effects
References
Chapter 5: Drugs of abuse
Abstract
Introduction
Prescription drugs
Illicit drugs
Over the counter (OTC) drugs
Other drugs
Conclusion
References
Chapter 6: Side effects of drugs used in the treatment of Alzheimer's disease
Abstract
Introduction
Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine)
Aducanumab
Memantine
Conclusion
References
Chapter 7: Anti-epileptic medications
Abstract
Gamma-aminobutyric acid (GABA) receptor agonists (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker & Choi, 2019 [R])
GABA reuptake inhibitors (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker and Choi, 2019 [R])
GABA transaminase inhibitors (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker and Choi, 2019 [R])
GABA analogues (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker and Choi, 2019 [R])
Sodium Channel Blockers (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker & Choi, 2019 [R])
Glutamate blockers (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker and Choi, 2019 [R])
Miscellaneous other mechanisms of action (Aronson, 2016 [R]; Maroney & Markovic, 2021 [R]; Walker & Ray, 2020 [R]; Walker & Choi, 2019 [R])
References
Chapter 8: Antihypertensive drugs
Abstract
Introduction
Special review: Skin cancer
Angiotensin converting enzyme inhibitors [SEDA-39, 183–187; SEDA-40, 263; SEDA-41, 219–220; SEDA-42, 215–216; SEDA-43, 249–250]
Angiotensin receptor blockers [SEDA-40, 263–264; SEDA-41, 220–221; SEDA-42, 216–218; SEDA-43, 250–251]
Beta blockers [SEDA-40, 264–265; SEDA-41, 221–222; SEDA-42, 218–221; SEDA-43, 251–254]
Calcium channel blockers [SEDA-40, 265; SEDA-41, 222–223; SEDA-42, 221–223; SEDA-43, 254–256]
Diuretics [SEDA-41, 223–224; SEDA-42, 223–224; SEDA-43, 256–257]
Alpha-2 agonists [SEDA-41, 224; SEDA-42, 224–225]
Vasodilators [SEDA-41, 224–225; SEDA-42, 225]
References
Chapter 9: Positive inotropic drugs and drugs used in dysrhythmias
Abstract
Cardiac glycosides [SEDA-41, 183–194; SEDA-42, 183–193; SEDA-43, 207–209]
Antidysrhythmic drugs
References
Chapter 10: Side effects of beta adrenergic antagonists and antianginal drugs
Abstract
Introduction
Beta-adrenoreceptor antagonists [SEDA-41, 197; SEDA-42, 195; SEDA-43, 219]
Bisoprolol
Carvedilol
Labetalol
Metoprolol
Nebivolol
Propranolol
Sotalol
Timolol
Calcium channel blockers [SEDA-41, 199; SEDA-42, 199; SEDA-43, 225]
Amlodipine
Diltiazem
Nifedipine
Verapamil
Inhibitors of fatty acid oxidation [SEDA-42, 203; SEDA-43, 233]
Trimetazidine
Late sodium inhibitor [SEDA-41, 203 SEDA-42; 20]
Nitrates [SEDA-43, 244]
Potassium channel activators [SEDA-41, 202]
References
Chapter 11: Side effects of anti-lipid medications
Abstract
HMG-CoA reductase inhibitors
PCSK9 inhibitors
Bile acid sequestrant
Fibric acid derivatives
Omega-3 fatty acids/icosapent ethyl
Niacin
Bempedoic acid
References
Chapter 12: Side effects of opioid analgesics and narcotic antagonists
Abstract
Introduction
Opioid full agonists [see Fig. 1; SEDA-24, 100; SEDA-26, 89; SEDA-39, 107; SEDA-41, 97; SEDA-42, 115]
Partial agonists [see Fig. 2; SEDA-24, 100; SEDA-26, 89; SEDA-39, 107; SEDA-41, 97; SEDA-42, 115]
Opioid antagonists [see Fig. 2; SEDA-24, 100; SEDA-26, 89; SEDA-39, 107; SEDA-41, 97; SEDA-42, 115]
Conclusion
References
Chapter 13: Anti-inflammatory and antipyretic analgesics and drugs used in gout
Abstract
Aniline derivatives [SEDA-42, 12; SEDA-43, 135]
Arylalkanoic acid derivatives [SEDA-42, 130; SEDA-43, 140]
NSAID class effects
Ketorolac [SEDA-42, 132; SEDA-43, 141]
Propionic acid derivatives [SEDA-42, 132; SEDA-43, 142]
Pyrazole derivatives [SEDA-42, 133; SEDA-43, 143]
Drugs used in the treatment of gout [SEDA-42, 136; SEDA-43, 146]
References
Chapter 14: Neuromuscular blocking agents and skeletal muscle relaxants
Abstract
Introduction
Depolarizing neuromuscular blocking agents
Nondepolarizing neuromuscular blocking agents
Neuromuscular blocker reversal agents
Skeletal muscle relaxants
References
Chapter 15: General anaesthetics and therapeutic gases
Abstract
Dexmedetomidine
Propofol
Urinary tract
Etomidate
Ketamine
Volatile agents
Sevoflurane
Liver
Urinary tract
Desflurane
Nitrous oxide
Methoxyflurane
References
Chapter 16: Side effects of local anesthetics
Abstract
Introduction
Articaine
Benzocaine
Levobupivacaine
Lidocaine
Management of patients with allergy to local anesthetics: Two case reports
Prilocaine
Ropivacaine
Combination drugs
Special review
Conclusion
Acknowledgement
References
Further reading
Chapter 17: Blood and blood treatments
Abstract
Introduction
Chimeric antigen receptor
Immunoglobulin
Monoclonal antibodies
Umbilical cord blood
Thrombopoietin receptor agonist
Glucocorticoid receptor agonist
Anticoagulants
Coagulation proteins
Platelet-rich plasma
References
Chapter 18: Drugs that affect blood coagulation, fibrinolysis and hemostasis
Abstract
Warfarin and direct-acting anticoagulants
Low molecular weight heparins (LMWH)
Prothrombotic agents
Anticoagulant reversal agents
Thrombolytic agents
References
Chapter 19: Beta-lactams and tetracyclines
Abstract
Cephalosporins
Penicillins
Tetracyclines and glycylcyclines
References
Chapter 20: Side effects of miscellaneous antibacterial drugs
Abstract
Tetracyclines
Lincosamides
Macrolides
Fluoroquinolones
Glycopeptides
Aminoglycosides
Oxazolidinones
Antibiotics, miscellaneous
References
Chapter 21: Antiviral drugs
Abstract
Drugs active against coronavirus disease 2019 (COVID-2019)
Drugs active against cytomegalovirus (CMV)
Drugs active against hepatitis B virus (HBV)
Drugs active against hepatitis C virus (HCV)
Drugs active against herpes simplex virus-1, -2 (HSV-1, HSV-2)
Drugs active against human immunodeficiency virus (HIV): Integrase inhibitors (INSTIs)
Drugs active against human immunodeficiency virus (HIV): Non-nucleoside reverse transcriptase inhibitors (NRTIs)
Drugs active against human immunodeficiency virus (HIV): Nucleoside/-tide reverse transcriptase inhibitors (NNRTIs)
Drugs active against human immunodeficiency virus (HIV): Protease inhibitors (PIs)
Drugs active against influenza virus: Neuraminidase inhibitor
Drugs active against influenza virus: Endonuclease inhibitor
Conclusion
References
Chapter 22: Antifungal drugs
Abstract
Allylamines
Azoles
Echinocandins
Polyenes
Triterpenoid
References
Chapter 23: Drugs used in the treatment of tuberculosis and leprosy
Abstract
Introduction
Organs and systems
Aminoglycosides
Bedaquiline
Clofazimine
Dapsone
Delamanid
Delpazolid
Ethambutol
Fluoroquinolones
Isoniazid
Linezolid
Pretomanid
Pyrazinamide
Rifampicin
Rifapentine
References
Chapter 24: Antihelminthic drugs
Abstract
Albendazole
Diethylcarbamazine
Ivermectin
Levamisole
Special review
Mebendazole
Moxidectin
Praziquantel
References
Chapter 25: Vaccines
Abstract
Viral vaccines
Parasitic vaccines
Cross references
References
Further reading
Chapter 26: Antiseptic drugs and disinfectants with experience of the second year of COVID-19 pandemic-related side effects
Abstract
Special review: COVID-19
All commonly used antiseptics and disinfectants [SEDA-37, 273; SEDA-40, 289; SEDA-43, 276]
Alcohols [SEDA-19, 235; SEDA-43, 279]
Aldehydes [SEDA-39, 209; SEDA-40, 289; SEDA-41, 251; SEDA-42, 247; SEDA-43, 279]
Guanidines
Benzalkonium compounds [SEDA-39, 212; SEDA-40, 292; SEDA-41, 253; SEDA-42, 249; SEDA-43, 281]
Triclosan [SEDA-37, 276; SEDA-39, 212; SEDA-40, 292; SEDA-41, 254; SEDA-42, 249]
Ethylene oxide [SEDA-36, 341; SEDA-37, 273; SEDA-38, 214; SEDA-41, 254]
Halogens
Ultraviolet (UV) light [SEDA-43, 281]
References
Chapter 27: Side Effects of Gastrointestinal Drugs
Abstract
Acid-impacting agents
Proton-pump inhibitors (PPIs) [SEDA-40, 463–466; SEDA-41, 408–412; SEDA-42, 362–366; SEDA-43, 415–419]
Antidiarrheal and antispasmodic agents
Antiemetic agents
Prostaglandins
Antiinflammatory agents
Miscellaneous agents
Biologics
References
Chapter 28: Side effects of insulin and oral antihyperglycemic drugs
Abstract
Introduction
Insulin and associated adverse effects [Fig. 1; SEDA-40, 541; SEDA-41, 498; SEDA-42, 445; SEDA-43, 451]
Oral antihyperglycemic drugs [see also Fig. 2] [SEDA-33, 894; SEDA-34, 688; SEDA-36, 648; SEDA-37, 526; SEDA-38, 454; SEDA-39, 435; SEDA-40, 540; SEDA-41, 496; SEDA-42, 443; SEDA-43, 451]
Conclusion
References
Chapter 29: Drugs that act on the respiratory tract
Abstract
Leukotriene modifiers [SEDA-36, 245; SEDA-37, 197; SEDA-38, 160; SEDA-39, 166; SEDA-40, 219; SEDA-41, 172; SEDA-42, 172; SEDA-43, 197]
Anticholinergic drugs [SEDA-36, 245; SEDA-37, 197; SEDA-38, 158; SEDA-39, 165; SEDA-40, 222; SEDA-41, 175; SEDA-42, 173; SEDA-43, 198]
Anti-fibrotic therapies [SEDA-40, 224; SEDA-41, 177; SEDA-42, 175; SEDA-43, 199]
Monoclonal antibodies [SEDA-38, 161; SEDA-39, 167; SEDA-40, 225; SEDA-41, 179; SEDA-42, 178; SEDA-43, 202]
References
Chapter 30: Metals and metal antagonists
Abstract
Ferroptosis
Susceptibility factors
Long term effects
Susceptibility factors
Long-term effects
References
Chapter 31: Side effects of anti-cancer medications
Abstract
DNA-crosslinking agents
Antimetabolites
Anti-microtubule agents
Antibiotics
Anti-HER2 antibodies
Anti-VEGF and anti-VEGFR antibodies
Tyrosine kinase inhibitors (TKIs)
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors
Proteasome inhibitors
Immune checkpoint inhibitors (ICIs)
Multiple anti-cancer drugs
References
Chapter 32: Side effects, toxicity and ADRs of monoclonal antibodies in multiple organ systems
Abstract
Introduction
Organ systems
References
Chapter 33: Thyroid hormones, iodine, and iodides, and antithyroid drugs
Abstract
Thyroid hormones (SEDA-42, 431–433; SEDA-43, 441–446)
Thionamides (SEDA-42, 433–439; SEDA-43, 446–448)
References
Chapter 34: Drugs for metabolic bone disease
Abstract
Introduction
Bisphosphonates
Burosumab
Calcitonin
Denosumab
Special review: Risks of denosumab discontinuation
Romosozumab
Parathyroid hormone and parathyroid hormone-related protein analogs
References
Chapter 35: Drugs used in ocular treatment
Abstract
Introduction
Medications used to treat glaucoma
Mydriatics
Mydriatic reversing agents
Anti-vascular endothelial growth factor (vegf) medications
Anti-inflammatory agents
Non-steroidal anti-inflammtory drugs (NSAIDs)
Dry eye disease
Anti-microbials
Special review: Cenegermin
Disclosure
References
Further reading
Chapter 36: Vitamins, amino acids, nutrition, and complementary and alternative medicine
Abstract
Introduction
Vitamin A [acitretin, alitretinoin, all-trans retinoic acid (atra), 13-cis retinoic acid (isotretinoin), carotenoids, etretinate] [SEDA-39, 345; SEDA-40, 431; SEDA-41, 387; SEDA-43, 513]
Vitamins of the B group [SEDA-39, 346; SEDA-40, 433; SEDA-41, 390; SEDA-43, 518]
Vitamin C (ascorbic acid) [SEDA-39, 349; SEDA-40, 435; SEDA-41, 392; SEDA-43, 519]
Vitamin D analogues [SEDA-39, 349; SEDA-40, 436; SEDA-41, 393; SEDA-43, 519]
Vitamin E (tocopherol) [SEDA-39, 351; SEDA-40, 439; SEDA-41, 394; SEDA-43, 521]
Vitamin K analogues [SEDA-39, 352; SEDA-40, 439; SEDA-41, 394; SEDA-43, 521]
Amino acids [SEDA-39, 352; SEDA-40, 440; SEDA-41, 394; SEDA-43, 522]
Enternal nutrition [SEDA-39, 352; SEDA-40, 442; SEDA-41, 396; SEDA-43, 523]
Parenteral nutrition [SEDA-39, 353; SEDA-40, 440; SEDA-41, 397; SEDA-43, 523]
Complementary and alternative medicine [SEDA-40, 609; SEDA-41, 559; SEDA-42, 483; SEDA-43, 493]
Conclusion
Acknowledgement
References
Further reading
Reviewers
Index of Drugs
Index of Drug-Drug Interactions
Index of Adverse Effects and Adverse Reactions

Sidhartha D. Ray

Sidhartha D. Ray, PhD, FACN serves as a Senior Professor of Pharmaceutical and Biomedical Sciences at The Touro College of Pharmacy at Manhattan, New York. Prior to this he served as Professor of Pharmaceutical Sciences for nearly 2 decades at the Arnold & Marie Schwartz College of Pharmacy and Health Sciences of Long Island University, New York, and as the founding chair of Pharmaceutical Science department at Manchester University College of Pharmacy, Indiana, USA. He has been in the health sciences academy for over 35 years mainly focusing on pharmacy teaching, research and service. Dr. Ray's research program focus on drug & chemical induced organ toxicology, mechanistic & molecular toxicology, adverse drug reaction mechanisms, side effects of a number of therapeutically relevant drugs and environmentally significant chemicals. Over the last two decades, Dr. Ray’s seminal discoveries have provided clear understandings on the dynamic role of apoptosis, necrosis and necraptosis during organotoxic reactions and have influenced the development of safety measures for a stunning variety of xenobiotics, phytochemicals and nutraceuticals. He is internationally recognized as a leader in the scientific community and was one of the front runners in exploring mechanisms of drug and chemical-induced programmed and un-programmed cell death in in-vivo models. His landmark studies on the interplay of bcl-2, bcl-xl, p53, bad and bax during acetaminophen induced cell death and its prevention by grape seed proanthocyanidin extract has earned worldwide citations. His peer recognition and acknowledged service contributions are reflected by his election into multiple international professional organizations, such as the Society of Toxicology (SOT), Society of Free Radical Biology & Medicine (SFRBM), American Society of Pharmacology & Experimental Therapeutics (ASPET), American Association of Colleges of Pharmacy (AACP) and American College of Nutrition (ACN). Dr. Ray is an Associate Editor of Encyclopedia of Toxicology (3rd Ed, Elsevier, 2014), and serves on the editorial boards of multiple prestigious international journals, including ‘Archives of Toxicology’ and ‘Oxidative Medicine & Cellular Longevity’. Based on his contributions to teaching, service and scholarship to health sciences in general, Dr. Ray received multiple prestigious awards, inc. the American Academy of Clinical Toxicology’s national research award (1996), ‘Fellow of the American College of Nutrition’ honor in 1999, David Newton Award for Excellence in Teaching Pharmacy (2005), the Biennial Abraham Krasnoff Memorial Award for Lifetime Scholarly Achievement (2008), Arnold & Marie Schwartz College of Pharmacy & Health Science’s ‘Wall-of-Fame’ honor (2011), the Society of Toxicology’s ‘Undergraduate Educator of the Year’ national award (2013), and the Manchester University’s ‘Outstanding Scholar of the Year’ award (2014). He currently serves on the SOT-NIH–NLM’s joint Toxlearn Project, SOT Undergraduate Task Force (2007 – present), and has previously served on the SOT’s Education Committee (2007 – 2010). In his lifetime, Dr. Ray has mentored research to numerous PharmD, MS, MD and PhD students in a number of areas of toxicology and biomedical sciences, made seminal contributions to the fields of pharmacology, toxicology, free radical biology, anticancer mechanism, phytochemicals, nutraceuticals & dietary supplements, and molecular safety sciences. Dr. Ray loves to promote ‘Lifelong Learning’ strategies to his students and clearly models his beliefs day in and day out. Visit URL: www.sidhartharay.com/ for more details.

Affiliations and expertise

Senior Professor of Pharmaceutical and Biomedical Sciences, Touro College of Pharmacy, Touro University System, Manhattan, NY, USA

Life Sciences

Physical Sciences & Engineering

Social Sciences & Humanities

Health